Among clinicians, initial awareness of the Wilms' tumor gene was limited mostly to pediatric
oncologists. Almost a decade ago, overexpression of Wilms' tumor 1 (WT1) was observed in …

Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …

Although rare, chronic myeloid leukemia (CML) represents an important paradigm for
understanding the molecular events leading to malignant transformation of primitive …

Abstract The Wilms' tumor (WT1) gene participates in leukemogenesis and is overexpressed
in most types of leukemia in humans. WT1 is also detectable in many types of lung, thyroid …

BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the
Philadelphia chromosome (Ph 1)-positive chronic myelogenous leukemia (CML) and a …

BCR/ABL regulates cell proliferation, apoptosis, differentiation and adhesion. In addition,
BCR/ABL can induce resistance to cytostatic drugs and irradiation by modulation of DNA …

We present the results of a novel method developed for evaluation of in situ amplification, a
molecular genetic method at the cellular level. Reverse transcription polymerase chain …

Abstract hnRNP A1 is a nucleocytoplasmic shuttling heterogeneous nuclear
ribonucleoprotein that accompanies eukaryotic mRNAs from the active site of transcription to …

Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients
requires integration of clinical and laboratory monitoring. Assessment of molecular response …